| Thu, Dec 3, 2009 | | • | Behind the Business: 3 Questions for Vical
at Motley Fool (Thu, Dec 3)
| | Mon, Nov 23, 2009 | | • | Vical Completes Final Patient Follow-Up in TransVax(TM) CMV Vaccine Phase 2 Trial
GlobeNewswire (Mon, Nov 23)
| | Tue, Nov 17, 2009 | | • | Big Pullback for Top Swine Flu Small-Caps
Indie Research (Tue, Nov 17)
| | Mon, Nov 16, 2009 | | • | Movers roundup: AeroVironment, Ciena
AP (Mon, Nov 16)
| | • | Vical will be added to biotech index, shares rise
AP (Mon, Nov 16)
| | • | Vical Added to NASDAQ Biotechnology Index
GlobeNewswire (Mon, Nov 16)
| | Wed, Nov 11, 2009 | | • | VICAL INC Financials
EDGAR Online Financials (Wed, Nov 11)
| | Tue, Nov 10, 2009 | | • | Vical's DNA Vaccine Technology Addresses Challenges of Emerging Diseases
GlobeNewswire (Tue, Nov 10)
| | Mon, Nov 9, 2009 | | • | Three Core Biotech Holdings: Isis, Ligand and Vical
at Seeking Alpha (Mon, Nov 9)
| | Fri, Nov 6, 2009 | | • | VICAL INC Files SEC form 10-Q, Quarterly Report
EDGAR Online (Fri, Nov 6)
| | Thu, Nov 5, 2009 | | • | New Star Analyst Rankings for Vical Incorporated
StarMine (Thu, Nov 5)
| | Wed, Nov 4, 2009 | | • | Vical, Inc. Q3 2009 Earnings Call Transcript
at Seeking Alpha (Wed, Nov 4)
| | • | CDC Sticking with 'Tried and True' Methods for Flu Vaccines
at Seeking Alpha (Wed, Nov 4)
| | • | Q3 2009 Vical Inc. Earnings Release - Before Market Open
CCBN (Wed, Nov 4)
| | • | VICAL INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
EDGAR Online (Wed, Nov 4)
| | • | Vical Reports Third Quarter 2009 Financial Results and Progress in Key Development Programs
GlobeNewswire (Wed, Nov 4)
| | Wed, Oct 28, 2009 | | • | Vical Announces News Release and Conference Call Schedule for Third Quarter 2009 Financial Results
GlobeNewswire (Wed, Oct 28)
| | Tue, Oct 27, 2009 | | • | Vical to Present at BIOCOM Investor Conference
GlobeNewswire (Tue, Oct 27)
| | Mon, Oct 26, 2009 | | • | Swine Flu Small-Cap Jumps on FDA Announcement
Indie Research (Mon, Oct 26)
| | • | Vical's Vaxfectin(R) Adjuvant Drives 200-Fold Increase in Antibody Responses With Sanofi-Pasteur Fluzone(R) Seasonal Influenza Vaccine
GlobeNewswire (Mon, Oct 26)
|
Add VICL News to My Yahoo!:
 
| |
|
0.22% Nasdaq 
Headlines
